Credit score: Artem Podrez from Pexels
New elementary analysis may assist fight treatment-resistant leukemia and stop relapses in kids and adolescents. A gaggle of scientists studied a sure kind of leukemia and recognized particular person stem cell-like cells chargeable for relapses in youngsters. They’ve additionally exactly characterised the molecular properties of those cells.
Acute lymphoblastic leukemia (ALL) is the commonest type of leukemia in kids and adolescents, accounting for about one-fifth of all cancers on this age group. Every year, roughly 550 to 600 kids and adolescents in Germany are identified with this type of blood most cancers. About 80% may be cured. Within the remaining circumstances, relapses happen attributable to resistance, resulting in poor prognoses.
Chemotherapy resistance is especially widespread in what is named T-ALL, a subtype of ALL. This current research reveals that the origin of the issue lies in a small inhabitants of treatment-resistant cells already current on the time of prognosis and which considerably improve throughout a relapse.
Analysis groups from EMBL, the Molecular Drugs Partnership Unit (MMPU), the Hopp Youngsters’s Most cancers Middle Heidelberg (KiTZ), and the German Most cancers Analysis Middle (DKFZ) analyzed particular person T-ALL cells from 18 leukemia sufferers at prognosis and after relapse, and in contrast their molecular profiles with leukemia cells from sufferers who didn’t endure a relapse. The findings are printed in Nature Communications.
Because the single-cell analyses revealed, many affected people already carried a small inhabitants of cells with stem cell-like properties early in the midst of the illness. These stem cell-like cells exhibit explicit resistance to chemotherapeutic brokers each in cell cultures and in mice. The invention’s medical relevance was additional substantiated in an evaluation of a lot of affected person samples: scientists extra incessantly discovered stem cell-like cells in sufferers for whom therapy with chemotherapeutic brokers was ineffective from the outset.
Growth of a stem cell-like immature dormant subclone through the improvement of relapse within the PDX-derived cells of a kid with T-ALL. Credit score: Nature Communications (2025). DOI: 10.1038/s41467-025-61222-1
Different most cancers research additionally recommend that cells with stem cell-like properties are why therapies finally cease working.
“Until now, however, it has not been possible to identify individual stem cell-like T-ALL cells responsible for relapses and to precisely characterize their molecular properties,” mentioned Jan Korbel, Interim Head of EMBL Heidelberg, Group Chief on the MMPU, and Analysis Group Chief on the DKFZ. He co-led the research with Andreas Kulozik, MMPU founder, Medical Director of the UKHD Division of Pediatric Oncology, Hematology and Immunology, Director of the Medical Program at KiTZ, and Head of the Medical Cooperation Unit Pediatric Leukemia at DKFZ.
The one-cell analyses additionally confirmed how the stem cell-like most cancers cells possess various molecular traits, which may be related for therapeutic choices: stem cell-like cells with sure gene exercise patterns had been indicative of a relapse. In accordance with the authors, the stem cell rating developed within the research may subsequently function a medical biomarker sooner or later to estimate the chance of relapse and, if mandatory, regulate therapy.
“With the approach developed in the study, which enables the individual analysis and molecular characterization of stem cell-like leukemia cells, we also aim to investigate in the future how different treatment regimens and therapeutics influence the development of these cells,” Kulozik defined.
The stem cell-like cells are a promising therapeutic goal for stopping relapses in kids and adolescents with T-ALL and for overcoming resistance, the authors hope.
Extra data:
Julia Costea et al, Position of stem-like cells in chemotherapy resistance and relapse in pediatric T-cell acute lymphoblastic leukemia, Nature Communications (2025). DOI: 10.1038/s41467-025-61222-1
Supplied by
European Molecular Biology Laboratory
Quotation:
Discovering a clue to the origin of treatment-resistant leukemia in youngsters (2025, August 5)
retrieved 5 August 2025
from https://medicalxpress.com/information/2025-08-clue-treatment-resistant-leukemia-kids.html
This doc is topic to copyright. Other than any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for data functions solely.
